Gyre Therapeutics Inc. (GYRE) exhibits 95.4% gross margins and 25.4% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 53.3x enterprise multiple and 4.8% implied options volatility.
Sustained 95.4% gross profitability converts into 9.9% operating margin and 25.4% ROIC, outpacing sector cost of capital.
ROIC: 25.4% // GM: 95.4%YoY revenue trajectory of +10.2% paired with -0.03% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +10.2% // FCF YLD: -0.03%Altman Z-Score of 14.33 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 14.33 // F-SCORE: 5/9Trading at 72.3x trailing P/E (67.2x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 72.3x // EV/EBITDA: 53.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $6.41 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.5% net margins.
NET MARGIN: 8.5% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for GYRE & activate live FRED threshold breach alerts.